Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
Joshua P Lewis, Kathleen A Ryan, Elizabeth A Streeten, Hilary B Whitlatch, Melanie Daue, Keith Tanner, James A Perry, Jeffrey R O'Connell, Alan R Shuldiner, Braxton D Mitchell · 2024
Read Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics by Joshua P Lewis, Kathleen A Ryan, Elizabeth A Streeten, Hilary B Whitlatch, Melanie Daue, Keith Tanner, James A Perry, Jeffrey R O'Connell, Alan R Shuldiner, Braxton D Mitchell (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11583987.txt.
Description
A peer-reviewed research article from Europe PMC (2024). Antiplatelet therapy with a P2Y12 receptor inhibitor, in combination with aspirin, is standard of care for medical management of patients with coronary artery disease, and flexibility in prescribing options among these medications offers great potential for individualizing patient care. Previously, we showed that a loss‐of‐function missense mutation (G143E) in carboxylesterase 1 (CES1), the primary enzyme responsible for clopidogrel degradation, significantly impacts on‐clopidogrel platelet aggregation and recurrent cardiovascular event risk.
Catalog record
| CREATOR | Joshua P Lewis, Kathleen A Ryan, Elizabeth A Streeten, Hilary B Whitlatch, Melanie Daue, Keith Tanner, James A Perry, Jeffrey R O'Connell, Alan R Shuldiner, Braxton D Mitchell |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |